Background: Video-assisted thoracic surgery (VATS) lobectomy provides a minimally invasive alternative for management of early stage non-small cell lung cancer, but is still only performed in a few specialized centers around the world. Questions about the safety of the surgery and its adequacy as a cancer operation remain hurdles for many surgeons.
INTRODUCTION
The earliest reports of minimally invasive lobectomies were published more than a decade ago. 1, 2 Although video-assisted thoracic surgery (VATS) has become the method of choice for many procedures formerly done via thoracotomy, the use of VATS for major lung resections has lagged substantially behind. The reasons are manifold. Performing anatomic lung resections by VATS is more complex than the relatively simple open operation and may require the use of special instruments. The intraoperative costs are higher. Perhaps most importantly, because lung cancer is the most common indication for performing lobectomy, the question of adequacy of the operation in satisfying surgical oncologic principles remains a hurdle in many surgeons' minds. The main considerations, therefore, in assessing whether to perform a minimally invasive lobectomy are adequacy as a cancer operation (as manifested by equivalent survival), safety in terms of complications and mortality, relative cost (including intraoperative and length of stay considerations), and benefits for the patients in terms of decreased pain and improved quality of life.
The definition of a VATS major lung resection can be problematic, or at least vague. In the literature, VATS lobectomy is a term used to describe a spectrum of operations from a mini-thoracotomy with rib-spreading and direct visualization through the wound to a completely minimally invasive approach with no rib-spreading and use of only thoracoscopic instruments. In interpreting studies of VATS lobectomy, careful review of the Methods section usually sheds light as to the nature of the operation performed. This needs to be taken into account when evaluating the evidence and forming conclusions.
METHODS
A systematic review of the literature was performed by accessing the MEDLINE database from 1966 through June 2005. The subject heading search terms "carcinoma, nonsmall-cell lung," "lung non small cell cancer," "lung adenocarcinoma," "lung alveolus cell carcinoma," "lung squamous cell carcinoma," "surgery," "cancer surgery," "lung surgery," "thoracic surgery, video-assisted," and "pneumo- nectomy" were combined with the following phrases used as text words: "non small cell lung," "lobectomy," "pneumonectomy," "VATS," "surgery," "thoracoscopy," "thoracoscopic," and "minimally invasive." These terms were then combined with the search terms for the following publication types and study designs: practice guidelines, systematic reviews, metaanalyses, randomized control trials (RCTs), phase III clinical trials, and major clinical studies.
Relevant articles (published in English) and abstracts were selected and reviewed by the authors, and the reference lists from those sources were searched for additional trials. Studies were divided into the following groups: RCTs, case-control studies, and case series. Patient consent and Internal Review Board approval were not required.
RESULTS
The literature published to date on VATS lobectomy or major lung resections is scant and largely of a lesser weight on the evidence scale. A few authors from various centers around the world are responsible for a large share of the studies, and the majority of the data is in the form of case series.
Randomized Control Trials
Few randomized control trials exist in this area ( Table  1) . [3] [4] [5] [6] Of the 3 published trials comparing open to VATS lobectomies, 2 examine clinical outcomes and 1 investigates biochemical markers. [3] [4] [5] The first and most wellknown RCT was published by Kirby and colleagues. 3 They randomized 61 patients with clinical stage I nonsmall cell lung cancer (NSCLC) to undergo lobectomy by VATS (31 patients) or muscle-sparing thoracotomy (30 patients). The VATS were performed without rib-spreading. One patient in the open group and 2 patients in the VATS group had benign disease and were excluded from analysis. In addition, 3 patients in the VATS group required conversion to thoracotomy and were also excluded from the analysis leaving 30 in the open and 25 in the VATS groups. There were few differences between the groups. The incidence of postoperative complications was less in the VATS group (6% versus 16%). There were no significant differences in operating time, blood loss, duration of chest tube placement, length of hospital stay, and incidence of disabling postthoracotomy pain (2 in the open versus 1 in the VATS group).
The other RCT comparing clinical outcomes between open and VATS lobectomy was published by a Japanese group. 4 Sugi and colleagues 4 randomized 100 patients with clinical stage IA lung cancer to open (52 patients) or VATS (48 patients) lobectomy and mediastinal lymph node dissection. The additional 2 patients in the open group were conversions from VATS and were analyzed in the open group. There were no significant differences in the recurrence rates or survival. The reported 3-and 5-year survivals were 93% and 85% in the open group and 90% and 90% in the VATS group, respectively. Of note, this is the only RCT to examine survival differences between VATS and open lobectomies.
A study comparing acute phase responses randomized 22 patients to VATS and 19 patients to open lobectomy. 5 They used a nonrib-spreading technique, and all patients had mediastinoscopy preoperatively. Blood samples were taken before and at various times in the first week after surgery. Both operations increased acute phase response A final RCT was performed comparing complete VATS (c-VATS) to assisted VATS (a-VATS). 6 The authors randomized patients with clinical stage I lung cancer to either a nonrib-spreading approach (c-VATS, 18 patients) or a mini-thoracotomy approach with rib-spreading (a-VATS, 16 patients). The authors found significantly shorter length of stay (11 versus 15 days), longer OR times, less blood loss, and lower serum markers (CRP, white blood cells) in the c-VATS group.
Case-Control Studies
A number of case-control studies examining a variety of outcomes have been performed on VATS major lung resections ( Table 2) . 8 -14,25-27 A number of other case-control series examining pain, changes in PFTs, nocturnal hypoxemia, and various markers of inflammation have been performed and are summarized in Table 2 . 10 -14 They generally favored VATS approaches, but the selection of controls was problematic. For example, in one study of cytokines before and after 
Case Series
Numerous case series have been published, many of which have been updated reflecting the ongoing experience of the authors, follow-up of patients, and modifications in technique. The series published in English with more than 100 patients are reviewed in Table 3 . [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Roviaro and colleagues 1 The other Japanese case series involved 106 patients, 95 of whom had a VATS procedure and the other 11 of whom were converted to thoracotomy (10% conversion rate). 17 Their main indication was clinical stage I. Tumor size was not a criterion. Their technique involved the use of a mini-thoracotomy and rib-spreading. They reported a 3-year survival of 93%, but only included the 82 patients 
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No spreading 2y 80% 3 1% mortality, 1.6% conversion for whom they had follow-up data for more than 6 months. Yim and colleagues 20 from Hong Kong published their series of 266 patients with tumors Ͻ5 cm for whom they attempted VATS resections. They converted to thoracotomy 19% of the time, and completed 214 VATS major lung resections. A rib-spreader was used. They reported a 22% incidence of nonfatal complications, 1 postoperative death, and 93% of patients alive at 2 years.
In the largest series of VATS major lung resections, McKenna and colleagues 21 reported on their experience of 1100 patients for whom they performed 1072 procedures with a conversion rate of 2.5%. There were no intraoperative deaths, and their mortality was only 0.8%. The complication rate was 15.3% with the most common complications being prolonged air leak and atrial fibrillation. Kaplan-Meier survival curves are presented, and extrapolation shows 5-year survivals for stage I and II cancers of approximately 80% and 60%, respectively. The incidence of port-site recurrence was 0.6%.
Finally, 2 independent series 22,23 using forms of simultaneous stapling have been published. This technique involves no rib-spreading, but variations on stapling the bronchus and vascular structures together without formal dissection. Lewis 22 reported a complication rate of 11.2% and 3-year survival of 83%. Of note, almost half of the patients were stage II. Gharagozloo 23 reported on 179 patients with a 5-year survival of 83%. They performed 29 right upper and middle bilobectomies (16%) in the series. This high number was performed as a conscious decision after some early recurrences in the N1 nodes between upper and middle lobes.
DISCUSSION
As detailed above, the bulk of the evidence is in the form of case series and case-control studies with few published RCTs. Synthesizing the data, some conclusions can be drawn:
• VATS lobectomy can be performed safely with equivalent mortality and complication rates to that of open lobectomy. This is based on the results of 2 small RCTs and a number of case-control trials and case series. 3,4,7,8,14 -27 • The survival of patients with stage I lung cancer following VATS lobectomy is equivalent to that of patients having open surgery. This is based on one small RCT, case-control studies, and the case series. 4,7,14 -27 • Patients experience less pain with VATS based on casecontrol studies. 1, 8, 9, 25, 26 • Length of hospital stay is similar to that of open procedures. One RCT showed no difference, and 3 casecontrol studies suggested it was shorter with VATS. 3, 8, 9, 26 Because the published evidence is thin, no definite recommendations can be made. The reality of the situation is that many surgeons are performing the procedure and many patients are requesting it. The data support that VATS lobectomy can be done safely and that the survival of early-stage patients is equivalent to that of thoracotomy. In terms of the postoperative course, although the data are mixed, there seems to be a suggestion that VATS patients have less pain and shorter hospital stays.
Differences in indications, technique, and extents of lymph node dissection make comparing across studies difficult. If one can perform the same operation in terms of anatomic dissection and lymph node removal as done through thoracotomy, then it would seem reasonable to offer a VATS lobectomy. The therapeutic role of lymph node dissection will remain unanswered for the time being until the survival results of the recently completely American College of Surgeons Oncology Group (ACOSOG) Z0030 study, comparing mediastinal lymph node dissection to sampling, are maturing. In the interim, few thoracic surgical oncologists would dispute the importance of lymph node dissection, particularly in view of the evidence that it does not increase morbidity or mortality and it aids in the selection of patients for adjuvant chemotherapy in the presence of lymph node involvement. 28 With that in mind, it would seem the real question of whether or not to perform VATS lobectomies hinges on the completeness of the lymph node dissection.
Few studies have been performed to assess the adequacy of lymph node dissection in VATS lobectomy. Sagawa and colleagues 29 conducted an interesting study by performing a VATS lobectomy and mediastinal lymph node dissection (with rib-spreading) followed by a conversion to thoracotomy at the same operation to assess the residual lymphatic tissue that remained unresected. In 29 patients, the mass of lymphatic tissue "missed" by VATS lobectomy was Ͻ3% of the amount resected, which they judged to be an adequate result. In a more conventional retrospective analysis, Watanabe et al 27 compared 191 VATS lobectomy patients with 159 thoracotomy patients. They demonstrated that the number of nodes dissected was similar in both groups. Shiraishi and colleagues 25 also noted in their small case-control study that the number of mediastinal lymph nodes dissected was similar in VATS and open groups. It should be noted that Japanese surgeons are generally regarded as being particularly aggressive in their lymph node dissections. This importance on lymphade-nectomy is reflected by the fact that all 3 studies addressing this issue in VATS lobectomy are from Japan.
Our practice has been to offer VATS lobectomy using no rib-spreading to patients with clinical stage I cancers with peripheral tumors Ͻ3 cm in diameter. Contraindications include the use of preoperative chemotherapy or radiotherapy. Lobectomy remains the standard of care for all early lung cancers. As such, the use of simultaneous stapling techniques is probably not warranted particularly in light of the increased number of bilobectomies performed by one center due to the inadequacy of their lymph node removals. It would seem that this is not the same operation as an open lobectomy.
CONCLUSION
There is certainly a need for further study. A large multicenter randomized trial comparing open lobectomy to VATS lobectomy would be ideal. However, the myriad of techniques used by different surgeons would make the standardization of the VATS arm difficult or impossible. Quality of life studies with validated instruments need to be performed to ascertain the impact of VATS. Another interesting avenue of investigation that has been embarked on but requires further study is the use of VATS in higher risk groups to see whether they fare better. Also, with the recent shift in clinical practice to adjuvant chemotherapy for more and more of our patients, there may be some additional benefit to VATS lobectomy if patients are better able to tolerate chemotherapy postoperatively. This should also be a subject of future studies.
